The combination of Valsacor with drugs containing K, and diuretics, on deducing K, increases the likelihood of hyperkalemia.
The drug interaction of Valsacor h and hd is determined by the presence of hydrochlorothiazide.
Its combination with drugs containing Li or K increases the likelihood of excess serum content of these substances. When this combination is prescribed, it is recommended that the concentration of electrolytes in the blood be monitored.
Monitor the plasma concentration of K followed by its combination with antiarrhythmics and antipsychotics, which promote activation of contractions of the heart muscle (the so-called "pirouette").
The likelihood of hypercalcaemia increases when this active substance is combined with preparations of Ca and vitamin D3.
Simultaneous use of Valsacor h and hd with hypoglycemic, antidotal drugs, pressor amines and tubocurarine may require corrections in their dosing.
Hydrochlorothiazide increases the likelihood of an increase in blood glucose levels from the action of ß-adrenoblockers and a hyperstat.
Cholinolytics contribute to an increase in its bioavailability, and cholestyramine and cholestipol decrease.
This substance increases the likelihood of the development of myelosuppressive action of cytostatic drugs and undesirable actions of amantadine.
Nonsteroidal anti-inflammatory drugs reduce its effectiveness, and the likelihood of developing renal failure increases.
The combination with methyldopa can provoke a reduction in the life cycle of red blood cells, with ethyl alcohol - orthostatic hypotension, with cyclosporine antibiotics - symptomatology of gout.
The combination with antibiotics of the tetracycline series increases their content in the urine.